Pharm D Solutions, LLC, Houston, TX

Is Pharm D Solutions, LLC registered with the FDA as a 503B outsourcing facility?

No matching record found in FDA’s registered outsourcing facility list (updated Nov 6, 2026) on Nov 15, 2026, searching by name and location. FDA’s compounding inspections and actions page labels it a 503A facility, with FDA’s note “Out of business”.

Does Pharm D Solutions, LLC hold a Texas pharmacy license?

No license with this exact name and city was found in the Texas State Board of Pharmacy file dated Nov 15, 2026. A pharmacy can hold its license under a different legal name, so this is not a finding that it is unlicensed. The Colorado State Board of Pharmacy also lists nonresident license OSP 6840 for Pharm D Solutions, Houston, TX, status Expired, as of Nov 15, 2026. The Illinois Department of Financial and Professional Regulation also lists nonresident license 054020058 for PHARM D SOLUTIONS LLC, HOUSTON, TX, status CLOSED, as of Nov 13, 2026.

Has Pharm D Solutions, LLC had a state board action or FDA letter?

FDA letters: no matching record found on FDA’s compounding inspections and actions page (current as of Oct 22, 2026, covering 2019 on) on Nov 15, 2026; the page lists 1 other action for Pharm D Solutions, LLC. Texas board disciplinary orders: not checked, because the board’s file flags orders only on a license, and no license matched this name and city.

FDA registers 503B outsourcing facilities; state boards of pharmacy license pharmacies, including 503A compounding pharmacies, and keep their own disciplinary records. Neither FDA list says which drugs a pharmacy makes.

Names in FDA records
Pharm D Solutions, LLC
Location
Houston, TX
Type as FDA labels it
503A
FDA’s note
Out of business
FDA 503B list
No matching record found
Form 483s on FDA’s actions page
0
Warning letters on FDA’s actions page
0
Latest action on that page
May 22, 2019
FDA Data Dashboard inspections
2 inspections: 2 OAI; 2 published Form 483s
Form 483 text on this page
1 Form 483, 16 observations
State board records
No exact match

FDA inspections and letters

FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists this pharmacy as Pharm D Solutions, LLC, a 503A facility, with 1 dated action.

Document
May 22, 2019Press release or statementFDA Press Release : Federal court enters consent decree against Texas compounder, Pharm D Solutions, LLC to cease the manufacturing of drugs intended to be sterile due to insanitary conditions (05/22/2019)FDA copy (archived)

FDA inspection classifications and published Form 483s

The FDA Data Dashboard, read Nov 15, 2026, lists Pharm D Solutions, LLC, Houston, TX (FEI number 3011043554), matched to this page by exact name, city and state. It lists 2 inspections: 2 OAI at that site, newest first, with FDA’s classification as worded on the dashboard. Dashboard firm profile.

Inspection endedClassificationProject area and product typeFEIInspection ID
Aug 28, 2018Official Action Indicated (OAI)Drug Quality Assurance (Drugs)30110435541063709
Jun 5, 2015Official Action Indicated (OAI)Drug Quality Assurance (Drugs)3011043554929073

Form 483s FDA has published for this site

FDA classifies each inspection when it is closed: No Action Indicated (NAI) means no objectionable conditions were found or they did not justify further action; Voluntary Action Indicated (VAI) means objectionable conditions were found but FDA is not prepared to take or recommend regulatory action; Official Action Indicated (OAI) means FDA recommended regulatory or administrative action. A classification is FDA’s, not a finding by this site. The dashboard lists inspections once FDA has classified them, from fiscal year 2009 on, so a recent inspection may not appear yet.

Form 483 observations

A Form 483 lists an FDA investigator’s observations at the end of an inspection. It is not a final FDA determination. In FDA’s words: “The FDA Form 483 does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any of its relevant regulations.” (FDA Form 483 FAQ). The firm may have answered or corrected these points; a response is not shown here unless FDA lists one.

FDA’s published Form 483 for this site has 16 numbered observations in all. Each observation is quoted from the PDF as FDA numbered it, with long ones cut and linked to the full form. Names of people on the form are not shown. What a Form 483 is; all 483s in this index.

Inspection Aug 13, 2018 to Aug 28, 2018: 16 observations

Firm on the cover
Pharm D Solutions, LLC, 1304 S Loop W, Houston, TX 77054 -4 010
FEI number
3011043554
Establishment type on the cover
Outsourcing Facility
FDA district office on the cover
4040 North Central Expressway, Suite 300 Dallas, TX 75204
Matched to this page by
FEI number on the cover; linked from Data Dashboard
FDA document
Read the full 483 (PDF on fda.gov)

This 483 is a scanned image. The text below is the PDF’s own text layer, which can misread characters; the PDF is the record.

Observation 1

Procedures designed to prevent microbiological contamination of drug products purpporting to be sterile are not established, written and followed.

Specifically,

A. Smoke studies performed under dynamic conditions were inadequate to verify the operators or activities do not affect the HEPA unidirectional airflow in the ISO 5 laminar air flow workbench(LAFW) where sterile injectable drugs are compounded. We reviewed videos of smoke studies conducted in January 2018 and July 2018. Studies under dynamic conditions in January 2018 showed a technician injecting a solution into an IV bag in the ISO 5 LAFW. Additionally, studies in July 2018 showed a technician waving their hands and arms around to simulate dispensing motions. No production equipment was present inside each of the ISO 5 LAFWs and no routine production was simulated in both instances. This is a repeat observation.

B. Your firm's media fills (MFs) are not being simulated under worst-case activities and conditions that

provide a challenge to aseptic operations. On 8/14/18, we reviewed MFs records dated 3/2118 and found they were not performed under the most stressful and challenging conditions. ...

Read the full 483 (PDF on fda.gov)

Observation 2

Specifically,

A. Your firm failed to reject batches of sterile drug product that did not meet specifications for potency. Your firm uses <Redacted B4> for HCG potency testing with acceptance criteria of <Redacted B4> Also the potency testing of Lipo MIC-12 has acceptance criteria of <Redacted B4> Examples of drug products still within expiry that either failed or are without potency testing were released and distributed include but are not limited to:

Lot Number Drug Product Test Failed % Potency 07192018:13 HCG 5000 IU No Potency Result NA 06262018:00 HCG 5000 IU Potency 58.7

06072018:03 HCG 12,000 IU Potency 77.6 07162018:84 HCG4000 IU Potency 38.7 06192018:36 HCG4000 IU Potency 53.8 05082018:39 HCG 5000 IU Potency 66.4 08012018:46 HCG 5000 IU Potency 36.5 07192018:64 HCG 12,000 IU No Potency Result NA 06192018:36 HCG4000 IU Potency 53.8 03212018:27 Lipo MIC-12 Potency 78.5, 79.7, 80.8 (3 repeat testing) 07302018:65 Lipo MIC-12 Potency 89.0

c. Your procedure for the release of sterile drug products is deficient. ...

Read the full 483 (PDF on fda.gov)

Observation 3

Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.

Specifically,

Your firm's environmental monitoring (EM) and personnel monitoring (PM) of the IOS 5 areas are inadequate. For example,

A. On 8/13/18, we observed the aseptic compounding of Trimix 150 mg/5 mg/50 mcg

Lyophilized Powder, lot 08132018:86 and Trimix 150 mg/10 mg/100 mcg Lyophilized Powder, lot 08132018:55. Your firm did not perform either surface monitoring or viable active air monitoring of the ISO 5 LAFWsKo ) (.21.) ]sterile drug product was compounded. The EM performed <Redacted B4> includes the passive air sampling & <Redacted B4> inside the ISO 5 LAFW. We also observed the <Redacted B4> placed in the <Redacted B4> Iwhere no compounding activities occuned.

'(bf<&I B. On 8/13/18, we observed technicians and <Redacted B4> sampled only one of the gloves, not both gloves, using <Redacted B4> at the <Redacted B4>

c. Viable active air sampling is only being performed under static conditions every <Redacted B4> during the clean room certification by an outside vendor.

D. ...

Read the full 483 (PDF on fda.gov)

Observation 4

Each batch of drug product pruporting to be sterile is not laboratory tested to determine conformance to such requirements.

Specifically,

Your firm did not test high-risk compounded drug product batches that were less than <Redacted B4> lmits for endotoxin and potency. Unvalidated in-house method is used for sterility testing. For example: drug product batches under <Redacted B4> lmits not tested prior to release including but not limited to Trimix Alprostadil/Phentolamine/Papavarin lots 08062018:52 and 08012018:08. This is a repeat observation.

Observation 5

Testing and release of drug product for distribution do not include appropriate laboratory determination of satisfactory conformance the final specifications and identity and strength length of each active ingredient prior to release.

Specifically,

E. Your firm does not test the preservative content in batches at time of release. Majority of your firm's compounded drug products contain <Redacted B4> a preservative. Examples of drug products contain <Redacted B4> are Trimix, Testosterone, and Lipo MIC-12.

F. Your firm lacks dissolution testing for Testosterone pellets to ensure the pellets do not immediately dissolve, that they remain integral, the active ingredient is released appropriately and at an acceptable rate. Additionally, your firm do not have method suitability for testing potency for your Testosterone pellets.

G. Your firm does not ensure the pH of the finished product meets written

Your firm does not ensure the pH of the finished product meets written specification prior to release. For example:

a. ...

Read the full 483 (PDF on fda.gov)

Observation 6

There are no written procedures for production and process controls designed to assure that the drug products have the identity, strength, quality, and purity they purport or are represented to possess.

Specifically,

There is no assurance you have control over the lyophilization of sterile drug products produced at your facility. For example:

A. There is no assurance the lyophilization system utilized by your firm is suitable for compounding of drug products. The User's Manual for <Redacted B4> mode <Redacted B4> and <Redacted B4> model <Redacted B4> describes the intended use whicn is for laboratory use to facilitate the lyophilization process.

(0) (4)

~ ; mode~ro) (4) _ and (b) (4)

; model b) (4 describes the intended use whicn is for laboratory use to facilitate the lyophilization process.

B. Your lyophilization process for processing of sterile drug product is deficient.Your firm utilized a <Redacted B4> freeze-drying system by <Redacted B4> 1. After <Redacted B4> the vials are <Redacted B4> . Your firm processed sterile lyophilized drugs using this process from October 2016 to April 2018. ;

c. ...

Read the full 483 (PDF on fda.gov)

Observation 7

Aseptic processing areas are deficient regarding the system for cleaning and disinfecting the room and equipment to produce aseptic conditions.

Specifically,

A. The cleaning agents for cleaning of the sterile drug production area are deficient. For example:

1. There is no expiration date on the sterile <Redacted B4> prep pads that are used in the ISO 5 LAFWs. On 8/13/18 and 8/20/18 operators were observed to use sterile <Redacted B4> prep pads on the IV bags in the LAFWs.

2. Non- sterile disinfectants <Redacted B4> and <Redacted B4> Cleaner and non-sterile non woven <Redacted B4> dry wipes are used to clean the ISO 7 clean room furniture and equipment, including but not limited to: tables, chairs, carts, mixer. <Redacted B4> and outside of the <Redacted B4> These items are then cleaned with sterile <Redacted B4> and non-sterile wipes.

B. The cleaning of the sterile drug production suite is deficient. For example:

1. On 8/15/18, we obse~¥i~d fiber-like material hanging from the HEPA filter housing of Hoodl.J[ 6f{21-) I model Kfi)- (21.]- -I . You produced

model o 4 on 8/lS/18. ....__.__._..____

2. ...

Read the full 483 (PDF on fda.gov)

Observation 8

Procedures designed to prevent microbiological contamination of drug products purporting to be sterile did not include validation of the sterilization process.

Specifically,

Your firm's <Redacted B4> and <Redacted B4> sterilization cycles have not been validated to ensure the cycles are capable of producing sterile compounded drug products. On 8/14/18, we reviewed <Redacted B4> validation records dated 6/8/18. We also reviewed <Redacted B4> calibration reported is dated 1/25/18. We found only the temperature mappings for both equipment and the <Redacted B4> for the <Redacted B4> were performed. Your firm did not conduct sterilization cycle validation specific to compounded drug products. The <Redacted B4> is use <Redacted B4> sterilize Phenol 5%, 7%, and all rubber stoppers and stopper caps. Additionally, the <Redacted B4> is used to sterilize Testosterone Cypionate and Testosterone Cypionate/Proprinate bulk drug product. ...

Read the full 483 (PDF on fda.gov)

Observation 9

Aseptic processing areas are deficient regarding systems for maintaining any equipment used to control the aseptic conditions.

Specifically, non-smooth areas that are difficult to clean were observed in the clean room. For example:

A. On 8/15/18, apparent rust inside a grooved area measured approximately two inches long on each side where the leg connects to the work surfaces was observed on the front right side of the <Redacted B4> LAFW, Hood <Redacted B4> model <Redacted B4>.

B. On 8/15/18, non-smooth welded surfaces were observed inside the LAFWs where the legs connect to the work surface on Hoods <Redacted B4> and <Redacted B4> models <Redacted B4> and <Redacted B4> respectively.

c. On 8/15/18, apparent chips and non-smooth surfaces were observed at the

lip of the top and middle tray inside the <Redacted B4> model <Redacted B4>

Observation 10

There is a failure to thoroughly review any lmexplained discrepancy and the failure of a batch or any of its components to meet any of its specifications whether or not the batch has been already distributed.

Specifically,

A. Your firm lacks environmental monitoring excursion investigations. For example, your firm does not identify a probable root cause and does not assess product impact.

1. On 3/8/17, a swab sample was collected from your firm's LAFW. Examination on 3/20/17 showed 9 cfus were recovered from the LAFW. From 3/8/17 to 3/20117, <Redacted B4> batches of sterile injectable products were compounded.

2. On 1/30/17, a swab sample and a viable passive air sample were collected from your

firm's LAFWs. Examination on 2/2/17 showed 1 cfu was recovered from each of the samples. From 1/30/17 to 2/2117, <Redacted B4> batches of sterile injectable products were compounded.

B. Your firm lacks investigations for yeast and mold species recovered from your firm's clean room facility. Your firm uses <Redacted B4> to monitor ISO 7 areas for yeast and mold growth. ...

Read the full 483 (PDF on fda.gov)

Observation 11

Clothing of personnel engaged in the manufacturing and processing of drug products is not appropriate for the duties they perform.

Specifically,

On 8/13/18, we observed the aseptic compounding of Trimix 150 mg/5 mg/50 mcg Lyophilized Powder, lot 08132018:86 and Trimix 150 mg/10 mg/100 mcg Lyophilized Powder, lot 08132018:55. We observed the following deficiencies.

5 A. We observed both technicians <Re dacted B4> and <Redacted B4> using bare hands to doing sterile clean room garments including sterile mask, sterile goggles, and sterile overalls in the ISO 7 Ante Room.

B. Sterile gowns and goggles are re-used in the same day. We observed

technicians <Redacted B4> and <Redacted B4> & hung goggles and overalls in the ISO 7 Ante Room when exiting the ISO 7 Clean Room facility. They re-donned the same goggles and overalls upon returning to the ISO 7 Clean Room resume aseptic compounding of sterile injectable drug products.

C. We observed exposed skin on the right cheek areas of both technicians. There was no minor in the Ante/Gowning room to check if gowning is adequate.

D. ...

Read the full 483 (PDF on fda.gov)

Observation 12

There is no written testing program designed to assess the stability characteristics of drug products.

Specifically,

B. The BUD of sterile drug products exceeded the expiry of a raw material

component used in production. For example: Raw material component Papaverine 70 mg/ml Stock Solution; expiry 10/4/18 was formulated into Trimix Papaverine/Phentolamine/Alprostadil 30 mg/1 mg/10 mcg Powder, lot 06062018:79; with expiry of 12/3/18.

Observation 13

Procedures designed to assure that corrects labels, labeling and packaging materials are used for drug products are not written and followed.

Specifically, your labeling operation including the issuance and approval of labels, labeling activities, reconciliation, reconditioning and examination of packaged and labeled products is deficient to ensure correct labels are applied on products and to prevent mix-ups. For example:

A. Finished product labels that were issued and approved by a pharmacist had inaccurate labeling information. The labels for LIPO-MIC W/ Methylcobalamin, lot 08132018:75/A that were printed, approved, and issued by Owner and Pharmacist JCD on 8/16/18 had inaccurate lot number "08142018:00" and production date "8/14/2018".

B. Finished product vials that were stored with released products in the refrigerator were observed <Redacted B4> with inaccurate labeling. On 8/16/18, 16 of bl 'vials of LIPO-MIC W/ Methylcobalamin, lot 08132018:75/A were observed to be labeled with inaccurate lot numbers and production dates.

C. Reconditioning activity was performed by a technician without first notifying a supervising pharmacist. ...

Read the full 483 (PDF on fda.gov)

Observation 14

Batch production and control records do not include complete labeling control records, including specimens or copies of all labeling used for each batch of drug product produced.

Specifically,

A. Your firm does not always include a label specimen in your batch records for the label applied on primary drug containers. For example, you did not have a label specimen for the following drugs:

1. Sermorelin/GHRP-2/GHRP-6 Mannitol 9 mg/9 mg/9 mg 300 mg, lot 06252018:30

2. Trimix Papaverine/Phentolamine/Alprostadil 30 mg/ 1 mg/10 mcg

Lyophilized Power, lot 06122018:31.

This is a repeat observation.

Observation 15

The labels of your outsourcing facility's drug products are deficient.

Specifically,

A. The statement, "This is a compounded drug" is not on all of your drug product labels. Examples of drug product labels that do not contain this statement are:

1. Testosterone Cypionate 200 mg/ml 30ml Injectable, lot 08062018:67A. 2. Testosterone Cypionate/Proprinate 200 mg/lOmg/lmL 30ml 200 mg/lOmg/lmL Injectable, lot 02272018:63/A. 3. Phenol 7°10 and Glycerin Aqueous Solution 10 ml 1432-10 7°10 Injectable, lot 08082018: 86. 4. Human Chorionic Gonadotropin/0.3 gm Mannitol Lyophilized Powder, lot 08062018:96. 5. Sermorelin/Ipamorelin 18 mg/15 mg Powder, lot 03272018:75. 6. Tri-Mix XL 150 mg/10 mg/100 mcg Lyophilized Powder, lot 06122018:06.

This is a repeat observation.

B. The quantity or volume is not on all of your drug product labels. Examples of drug product labels that do not contain the quantity or volume are:

1. Human Chorionic Gonadotropin/0.3 gm Mannitol Lyophilized Powder, lot 08062018:96. 2. Sermorelin/Ipamorelin 18 mg/15 mg Powder, lot 03272018:75. 3. Tri-Mix XL 150 mg/10 mg/100 mcg Lyophilized Powder, lot 06122018:06. 4. ...

Read the full 483 (PDF on fda.gov)

Observation 16

Your outsourcing facility did not submit a report to FDA identifying the drugs compounded during the previous six month period.

Specifically,

Your firm did not submit a report in June 2018 that identify drug products compounded from January 2018 to June 2018. Some of the sterile compounded drugs produced between January 2018 and June 2018 were:

APOMORPHINE 12MG TROCHE 12MG TROCHE

BACTERIOSTATIC WATER FOR INJECTION 10 ML 10 ML INJECTABLE B-COMPLEX B-1, B-6, B-3, B-12, B-5 INJECTABLE

BI-MIX PAPAVERINE / PHENTOLAMINE (LYO) 150 MG/ 5 MG POWDER CAFFEINE AND SODIUM BENZOATE INJECTION 125 MG/ 125 MG/ ML INJECTABLE

EPINEPHERINE 1 MG/ lML 3 ML lMG/ ML I NJECTABLE HCG LYOPHOLIZED 5000 IU INJECTABLE LIPO MIC-12 COMPOUND INJECTABLE METHYLCOBALAMIN INJECTABLE in 1 MG/ ML 10 ML 1 MG and 1 MG/ ML 30 ML 1 MG PHENOL 5°10 AND GLYCERIN AQUEOUS SOLUTION 10 ML 1431-10 5°10 INJECTABLE SERMORELIN / IPAMORELIN 18 MG/ 15 MG POWDER SILDENAFIL / APOMORPHINE TROCHE 150 MG/ 12 MG TROCHE TESTOSTERONE 200 MG/ ML GRAPESEED OIL 30 ML 200 MG/ ML I NJECTABLE THYROID 15 MG CAPSULE PINK/ AQUA BLUE 15 MG CAPSULE

TRIMIX BM 3 PAPAVERINE 60 MG/ PHENTOLAMINE 4 MG INJECTABLE

This is a repeat observation.

Linked 483s whose text is not shown

State board of pharmacy records

No license with this exact name and city was found in the Texas State Board of Pharmacy file dated Nov 15, 2026. A pharmacy can hold its license under a different legal name, so this is not a finding that it is unlicensed. Board file.

What this covers: The file marks whether a license has prior disciplinary orders (column DISP ACTN, Y or N) but does not list them; the orders are on the board’s license lookup, which this index does not copy. The board says orders entered more than 10 years ago are not online.

Nonresident licenses in other states

These boards list a nonresident license whose record names this pharmacy’s own name, city and state.

Colorado State Board of Pharmacy, file dated Nov 15, 2026 (Colorado).

LicenseType as the board gives itName on the board recordLocationStatus
OSP 6840OSPPharm D SolutionsHouston, TXExpired

Illinois Department of Financial and Professional Regulation, file dated Nov 13, 2026 (Illinois).

LicenseType as the board gives itName on the board recordLocationStatus
054020058LICENSED PHARMACYPHARM D SOLUTIONS LLCHOUSTON, TXCLOSED

This page restates FDA’s lists and state board of pharmacy records. A Form 483, letter or board action is not a finding by this site, and a missing record is not a finding either way. A state license is matched only on the same name, city and state. Follow each link for the original document. Report an error or add a company response.

Sources

Records last pulled Nov 15, 2026. Every entry links to the original public record.